CMS actuaries attribute an increase in health spending in 2014 to the expansion of Medicaid and private health insurance coverage and rapid growth in retail drug spending, particularly for new hep C drugs.
The full picture of the remarkable uptake of the new generation of hepatitis C drugs and the impact of coverage expansions led by the Affordable Care Act on national health spending for 2014 is now clear.
The dual factors of coverage expansion and rapid growth in retail prescription drug spending led to a much faster rate...
Clarity on what transferable exclusivity vouchers may look like for new antimicrobial drugs could be nearing. Denmark’s new presidency of the Council of the EU has prioritized concluding its negotiations with European Parliament over the legislative overhaul of the EU’s pharmaceutical legislation.
After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.
Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.
